Chronic inflammation in end-stage renal disease and dialysis

Gabriela Cobo, Bengt Lindholm, Peter Stenvinkel, Gabriela Cobo, Bengt Lindholm, Peter Stenvinkel

Abstract

Under normal conditions, inflammation is a protective and physiological response to various harmful stimuli. However, in several chronic debilitating disorders, such as chronic kidney disease, inflammation becomes maladaptive, uncontrolled and persistent. Systemic persistent inflammation has, for almost 20 years, been recognized as a major contributor to the uraemic phenotype (such as cardiovascular disease, protein energy wasting, depression, osteoporosis and frailty), and a predictor of cardiovascular and total mortality. Since inflammation is mechanistically related to several ageing processes (inflammageing), it may be a major driver of a progeric phenotype in the uraemic milieu. Inflammation is likely the consequence of a multifactorial aetiology and interacts with a number of factors that emerge when uraemic toxins accumulate. Beside interventions aiming to decrease the production of inflammatory molecules in the uraemic milieu, novel strategies to increase the removal of large middle molecules, such as expanded haemodialysis, may be an opportunity to decrease the inflammatory allostatic load associated with retention of middle molecular weight uraemic toxins.

Figures

FIGURE 1
FIGURE 1
Available therapeutic strategies for persistent inflammation in CKD. ACE, angiotensin-converting enzyme; HDx, Expanded hemodialysis; Ol-HDF, On-line hemodialfiltration.

References

    1. Levin A, Tonelli M, Bonventre J. et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 2017; 390: 1888–1917
    1. Stenvinkel P, Heimbürger O, Paultre F. et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899–1911
    1. Zimmermann J, Herrlinger S, Pruy A. et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648–658
    1. Gupta J, Mitra N, Kanetsky PA. et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 2012; 7: 1938–1946
    1. Eustace JA, Astor B, Muntner PM. et al. Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int 2004; 65: 1031–1040
    1. Stenvinkel P, Wanner C, Metzger T. et al. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002; 62: 1791–1798
    1. Carrero JJ, Stenvinkel P.. Inflammation in end-stage renal disease–what have we learned in 10 years? Semin Dial 2010; 23: 498–509
    1. Jankowska M, Cobo G, Lindholm B. et al. Inflammation and protein-energy wasting in the uremic milieu. Contrib Nephrol 2017; 191: 58–71
    1. Sun J, Axelsson J, Machowska A. et al. Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD. Clin J Am Soc Nephrol 2016; 11: 1163–1172
    1. Kooman JP, Kotanko P, Schols AM. et al. Chronic kidney disease and premature ageing. Nat Rev Nephrol 2014; 10: 732–742
    1. Amdur RL, Feldman HI, Gupta J. et al. Inflammation and progression of CKD: the CRIC study. Clin J Am Soc Nephrol 2016; 11: 1546–1556
    1. Evenepoel P, Poesen R, Meijers B.. The gut-kidney axis. Pediatr Nephrol 2016; 32: 2005–2014
    1. Anders HJ, Andersen K, Stecher B.. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 2013; 83: 1010–1016
    1. Wang F, Jiang H, Shi K. et al. Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrology (Carlton) 2012; 17: 733–738
    1. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428–435
    1. Karin M, Lawrence T, Nizet V.. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006; 124: 823–835
    1. Kooman JP, Dekker MJ, Usvyat LA. et al. Inflammation and premature aging in advanced chronic kidney disease. Am J Physiol Renal Physiol 2017; 313: F938–FF50
    1. Vanholder R, De Smet R, Glorieux G. et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934–1943
    1. Vanholder R, Pletinck A, Schepers E. et al. Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update. Toxins (Basel) 2018; 10: E33.
    1. Massy ZA, Liabeuf S.. Middle-molecule uremic toxins and outcomes in chronic kidney disease. Contrib Nephrol 2017; 191: 8–17
    1. Castillo-Rodríguez E, Pizarro-Sánchez S, Sanz AB. et al. Inflammatory cytokines as uremic toxins: “Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son”. Toxins (Basel) 2017; 9: E114.
    1. Neirynck N, Eloot S, Glorieux G. et al. Estimated glomerular filtration rate is a poor predictor of the concentration of middle molecular weight uremic solutes in chronic kidney disease. PLoS One 2012; 7: e44201.
    1. Kalocheretis P, Revela I, Spanou E. et al. Strong correlation of B2-microglobulin (B2-m) with procalcitonin (PCT) in the serum of chronic hemodialysis patients: a role for infections in the dialysis-related amyloidosis? Ren Fail 2008; 30: 261–265
    1. Cheung AK, Rocco MV, Yan G. et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006; 17: 546–555
    1. Lorenzo Sellares V, Torregrosa V.. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. Nefrologia 2008; 28 (Suppl 3): 67–78
    1. Smith LK, He Y, Park JS. et al. β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. Nat Med 2015; 21: 932–937
    1. Stenvinkel P, Ketteler M, Johnson RJ. et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia–the good, the bad, and the ugly. Kidney Int 2005; 67: 1216–1233
    1. Cohen SD, Phillips TM, Khetpal P, Kimmel PL.. Cytokine patterns and survival in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 1239–1243
    1. Cobo G, Qureshi AR, Lindholm B, Stenvinkel P.. C-reactive protein: repeated measurements will improve dialysis patient care. Semin Dial 2016; 29: 7–14
    1. Xu H, Huang X, Risérus U. et al. Dietary fiber, kidney function, inflammation, and mortality risk. Clin J Am Soc Nephrol 2014; 9: 2104–2110
    1. Stenvinkel P. Can treating persistent inflammation limit protein energy wasting? Semin Dial 2013; 26: 16–19
    1. Viana JL, Kosmadakis GC, Watson EL. et al. Evidence for anti-inflammatory effects of exercise in CKD. J Am Soc Nephrol 2014; 25: 2121–2130
    1. Shiels MS, Katki HA, Freedman ND. et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst 2014; 106: dju294.
    1. Heimbürger O, Stenvinkel P.. Statins to treat chronic inflammation in dialysis patients–is this feasible? Perit Dial Int 2007; 27: 254–257
    1. Merino A, Alvarez-Lara MA, Ramirez R. et al. Losartan prevents the development of the pro-inflammatory monocytes CD14+CD16+ in haemodialysis patients. Nephrol Dial Transplant 2012; 27: 2907–2912
    1. Makówka A, Olejniczak-Fortak M, Nowicki M.. A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients–a pilot open label study. Kidney Blood Press Res 2012; 36: 18–25
    1. Gamboa JL, Pretorius M, Todd-Tzanetos DR. et al. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. J Am Soc Nephrol 2012; 23: 334–342
    1. Bucharles S, Barberato SH, Stinghen AE. et al. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. J Ren Nutr 2012; 22: 284–291
    1. Sun PP, Perianayagam MC, Jaber BL.. Endotoxin-binding affinity of sevelamer: a potential novel anti-inflammatory mechanism. Kidney Int Suppl 2009; 76: S20–S25
    1. Caglar K, Yilmaz MI, Saglam M. et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008; 3: 61–68
    1. González-Espinoza L, Rojas-Campos E, Medina-Pérez M. et al. Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. Nephrol Dial Transplant 2012; 27: 2023–2028
    1. Smolen JS, Beaulieu A, Rubbert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987–997
    1. Ridker PM, Thuren T, Zalewski A, Libby P.. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162: 597–605
    1. Chin MP, Bakris GL, Block GA. et al. Bardoxolone methyl improves kidney function in patients with chronic kidney disease stage 4 and type 2 diabetes: post-hoc analyses from bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes study. Am J Nephrol 2018; 47: 40–47
    1. Yu X. The evolving patterns of uremia: unmet clinical needs in dialysis. Contrib Nephrol 2017; 191: 1–7
    1. Eloot S, Van Biesen W, Dhondt A. et al. Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int 2008; 73: 765–770
    1. Meert N, Eloot S, Waterloos MA. et al. Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant 2008; 24: 562–570
    1. Wolley M, Jardine M, Hutchison CA.. Exploring the clinical relevance of providing increased removal of large middle molecules. Clin J Am Soc Nephrol 2018; 13: 805–814
    1. Alves FC, Sun J, Qureshi AR. et al. The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease. PLoS One 2018; 13: e0190410.
    1. Ronco C. The rise of expanded hemodialysis. Blood Purif 2017; 44: I–VIII
    1. Mitra S, Kharbanda K.. Effects of expanded hemodialysis therapy on clinical outcomes. Contrib Nephrol 2017; 191: 188–199
    1. Kirsch AH, Rosenkranz AR, Lyko R, Krieter DH.. Effects of hemodialysis therapy using dialyzers with medium cut-off membranes on middle molecules. Contrib Nephrol 2017; 191: 158–167
    1. Kirsch AH, Lyko R, Nilsson LG. et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant 2017; 32: 165–172
    1. Zickler D, Schindler R, Willy K. et al. Medium cut-off (MCO) membranes reduce inflammation in chronic dialysis patients-a randomized controlled clinical trial. PLoS One 2017; 12: e0169024.
    1. Belmouaz M, Diolez J, Bauwens M. et al. Comparison of hemodialysis with medium cut-off dialyzer and on-line hemodiafiltration on the removal of small and middle-sized molecules. Clin Nephrol 2018; 89: 50–56

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner